Alexandra Hospital
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Alexandra Hospital in Athens, clinical research in cardiovascular diseases focuses on major conditions such as heart failure, atrial fibrillation, atherosclerotic cardiovascular disease, stroke, and transthyretin-mediated amyloid cardiomyopathy. The studies are aimed at improving prevention, reducing complications, and evaluating new treatment options for people at high cardiovascular risk.
- Research on heart failure is evaluating whether new therapies can lower hospitalizations and cardiovascular deaths.
- Trials in atrial fibrillation are comparing approaches to prevent stroke and systemic embolism while balancing bleeding risk.
- Studies in atherosclerotic cardiovascular disease and elevated lipoprotein(a) are exploring ways to reduce future heart attacks and urgent revascularization.
- Work in amyloid cardiomyopathy is examining longer-term safety and tolerability of treatments for this rare heart condition.
This area reflects a strong interest in both common and complex cardiac disorders, with a clear focus on prevention, symptom control, and better long-term outcomes.
Hemic and Lymphatic Diseases
The Plasma Cell Dyscrasias Unit at Alexandra Hospital supports a broad portfolio of studies in hematologic cancers and related blood disorders. Key diseases include multiple myeloma, Waldenström’s macroglobulinemia, and diffuse large B-cell lymphoma, with research also touching on other aggressive blood malignancies. The overall goal is to improve disease control and extend survival.
- Studies in multiple myeloma are testing new maintenance and combination treatment strategies for newly diagnosed and relapsed disease.
- Research in Waldenström’s macroglobulinemia is focused on patients with difficult-to-treat or previously treated disease.
- Trials in lymphoma are assessing whether adding novel therapies can improve progression-free survival.
- The site’s hematology research aims to refine treatment effectiveness while addressing safety and tolerability in blood cancers.
These studies highlight a specialized focus on plasma cell disorders and other lymphoid malignancies, combining clinical care with research on more effective cancer treatment.
Neoplasms
The cancer research program at Alexandra Hospital spans multiple solid tumors, including breast cancer, lung cancer, endometrial cancer, prostate cancer, colon cancer, and urothelial carcinoma. Across these studies, investigators are evaluating new therapies, improving disease-free and progression-free survival, and helping define better treatment strategies for patients with advanced or high-risk disease.
- In breast cancer, trials are examining endocrine-based strategies and novel targeted treatments to reduce recurrence and slow progression.
- Lung cancer research includes studies for both non-small cell and small cell disease, with attention to difficult-to-treat molecular subtypes.
- Studies in endometrial cancer and colon cancer are testing peri-operative and adjuvant approaches to improve cure rates.
- Additional oncology work includes prostate cancer, kidney cancer, and urothelial cancer, where the aim is to improve response and delay disease worsening.
Overall, the site shows a broad commitment to oncology research, with emphasis on advanced disease, recurrence prevention, and treatment comparison across several cancer types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 16 therapeutic areas and 15 of 297 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 283 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 44 by active trials.
- 1Merck Sharp & Dohme LLC9active
lock +43 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International19trials
lock +38 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Alexandra Hospital
lock Showing 1 of 247 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 2022-501606-35-00 – Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA). | AbbVie Deutschland GmbH & Co. KG | Phase I | Not Yet Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 297 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 56 | Unknown | 2016-11-21 | 2026-07-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
